Predicting Return of Sense of Smell in Adults with Chronic Rhinosinusitis and Nasal Polyps Treated with Dupilumab

What this Trial Is About

Researchers are investigating what factors predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps CRSwNP who are being treated with dupilumab. This observational study focuses on two key questions whether obstruction of the olfactory cleft and electrophysiological signals from breathing and sniffing behavior can predict olfactory restoration. Participants include those with persistent smell loss despite prior sinus surgery. Participants starting the standard dose of dupilumab 300mg every two weeks will undergo assessments to measure the degree of olfactory cleft obstruction and electrophysiological activity in the olfactory bulb. These evaluations occur over 24 weeks of treatment with dupilumab. The study aims to follow participants for 6 months while monitoring these parameters. During the study, participants will have their sense of smell tested using the Brief Smell Identification Test over 26 weeks. Researchers will track changes in olfactory function alongside physiological measurements. This monitoring will help identify predictors of smell recovery. The total duration of observation spans approximately 6 months, and participants will be assessed regularly to gather data on olfactory status and related signals.

Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.